Ninlaro
Ninlaro ingredients
| Active ingredient | Strength |
|---|---|
| Ixazomib Citrate | 2.3 mg/1, 4 mg/1, 3 mg/1 |
What Ninlaro is used for
The FDA lists the approved uses on the official label (below). In the EU, ixazomib is approved as Ninlaro for:
Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ninlaro
- Generic name
- Ixazomib
- Made by
- Takeda Pharmaceuticals America, Inc.
- Forms
- Capsule
- Given
- Oral
- Drug class
- Proteasome Inhibitor
- FDA approval
- New drug application (NDA) NDA208462
- On the US market since
- 2015
Official information
- Ninlaro prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ixazomib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ninlaro?
Ninlaro (Ixazomib) is a cancer medicine made by Takeda Pharmaceuticals America, Inc., approved by the US FDA.
What are the ingredients of Ninlaro?
Ninlaro contains Ixazomib Citrate (2.3 mg/1, 4 mg/1, 3 mg/1).
Is Ninlaro approved in Europe?
The same active substance is approved in the EU as Ninlaro.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA